Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 4/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FADS1 | O60427 | 2/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489173 | 0.85 | NSD2 (0.42) | NSD2TDP2ALOX5KDM4ELMNA | |
| SCHEMBL4319628 | 0.83 | ALOX5 (0.40) | NSD2TDP2ALOX5DRD2DRD3 | |
| SCHEMBL4501815 | 0.83 | MEN1 (0.47) | KDM4ELMNAGAAMEN1ALDH1A1 | |
| SCHEMBL4456810 | 0.81 | CA12 (0.41) | ALOX5KDM4ELMNAGAAFADS1 | |
| SCHEMBL4454521 | 0.79 | MGLL (0.44) | ALOX5KDM4ELMNAGAAMEN1 | |
| SCHEMBL4471023 | 0.79 | MEN1 (0.44) | KDM4ELMNAGAAMEN1ALDH1A1 | |
| SCHEMBL4566658 | 0.78 | CA12 (0.38) | TDP2KDM4ELMNAGAAMEN1 | |
| SCHEMBL4455334 | 0.77 | GAA (0.42) | KDM4ELMNADRD2DRD3NOTUM | |
| SCHEMBL4492543 | 0.76 | GAA (0.61) | NSD2TDP2ALOX5DRD2DRD3 | |
| SCHEMBL4316275 | 0.76 | NSD2 (0.43) | NSD2TDP2ALOX5DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286813-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286813-A1 | Thioxanthine Derivatives and Their Use as Inhibitors of MPO | MPO, XDH, EPX | NSD2 4186/4885TDP2 809/4885ALOX5 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.